Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations
Table 1
Demographic, clinical, and laboratory characteristics of lung cancer patients and control subjects.
Variable
Lung cancer patients ()
Control subjects ()
value
Age (years)
65 (46-82)
63 (43-81)
0.49
Male, (%)
30 (20.3)
20 (20.0)
0.08
Body mass index (kg/m2)
25.0 (14.6-40.6)
26.9 (19.9-36.2)
<0.0001
Clinical features
Current smoking, (%)
53 (35.8)
10 (10.0)
<0.0001
Arterial hypertension, (%)
48 (32.4)
55 (55.0)
0.3
Diabetes mellitus, (%)
12 (8.1)
7 (7.0)
0.19
Previous stroke, (%)
4 (2.7)
8 (8.0)
0.09
Medications
Statin, (%)
26 (17.6)
42 (42.0)
0.004
Aspirin, (%)
25 (16.9)
38 (38.0)
0.005
Laboratory investigations
WBC (103/μl)
9.2 (8.4-10.0)
6.0 (5.8-6.2)
<0.0001
Hemoglobin (g/dl)
12.8 (12.6-13.0)
13.9 (13.7-14.1)
<0.0001
Hematocrit (%)
39.2 (38.7-39.7)
41.3 (40.9-41.8)
<0.0001
Platelets (103/μl)
309 (298-320)
237 (229-245)
<0.0001
Creatinine (μM)
74 (72-76)
68 (66-69)
0.028
D-dimer (ng/ml)
477 (402-552)
225 (217-233)
<0.0001
Fibrinogen (g/l)
3.16 (3.10-3.25)
2.47 (2.24-3.10)
<0.0001
Plasminogen (%)
102.8 (101.0-104.6)
104.8 (102.9-106.6)
0.79
HRG (μg/ml)
37.0 (36.2-37.9)
68.4 (66.5-70.2)
<0.0001
Fibrin clot characteristics
(10-9 cm2)
6.65 (6.54-6.76)
9.05 (8.84-9.26)
<0.0001
Lag phase (s)
39.0 (38.6-39.4)
42.5 (40-46)
<0.0001
(405 nm)
0.85 (0.84-0.86)
0.80 (0.79-0.81)
<0.0001
Clot lysis time (min)
99.0 (97.2-100.8)
75.5 (73.7-77.3)
<0.0001
Data are given as number (percentage), , or median (interquartile range). Abbreviations: WBC: white blood cells; HRG: histidine-rich glycoprotein; : fibrin clot permeability coefficient.
